{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:09:23Z","timestamp":1790705363929,"version":"4.1.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T00:00:00Z","timestamp":1689724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T00:00:00Z","timestamp":1689724800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Biotest A.G."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1007\/s40268-023-00430-w","type":"journal-article","created":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T13:01:50Z","timestamp":1689771710000},"page":"245-255","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Biochemical Characterization of a New 10% IVIG Preparation [IgG Next Generation (BT595)\/Yimmugo\u00ae] Obtained from a Manufacturing Process Preserving IgA\/IgM Potential of Human Plasma"],"prefix":"10.1007","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6335-9748","authenticated-orcid":false,"given":"Christian","family":"Duellberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achim","family":"Hannappel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Kistner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Maneg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,19]]},"reference":[{"key":"430_CR1","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1093\/intimm\/dxx039","volume":"29","author":"C Galeotti","year":"2017","unstructured":"Galeotti C, Kaveri S, Bayry J. IVIG-mediated effector functions in autoimmune and inflammatory diseases. Int Immunol. 2017;29:491\u20138.","journal-title":"Int Immunol"},{"key":"430_CR2","doi-asserted-by":"crossref","unstructured":"Vitiello G, Emmi G, Silvestri E, di Scala G, Palterer B, Parronchi P. Intravenous immunoglobulin therapy: a snapshot for the internist. Intern Emerg Med. Springer-Verlag Italia s.r.l.; 2019. p. 1041\u20139.","DOI":"10.1007\/s11739-019-02150-z"},{"key":"430_CR3","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1111\/j.1365-2249.2007.03545.x","volume":"151","author":"A Gonzalez-Quintela","year":"2008","unstructured":"Gonzalez-Quintela A, Alende R, Gude F, Campos J, Rey J, Meijide LM, et\u00a0al. Serum levels of immunoglobulins (IgG, IgA, IgM) in a general adult population and their relationship with alcohol consumption, smoking and common metabolic abnormalities. Clin Exp Immunol. 2008;151:42\u201350.","journal-title":"Clin Exp Immunol"},{"key":"430_CR4","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s13613-020-00740-1","volume":"10","author":"A Nierhaus","year":"2020","unstructured":"Nierhaus A, Berlot G, Kindgen-Milles D, M\u00fcller E, Girardis M. Best-practice IgM- and IgA-enriched immunoglobulin use in patients with sepsis. Ann Intensive Care. 2020;10:132.","journal-title":"Ann Intensive Care"},{"key":"430_CR5","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13613-019-0501-3","volume":"9","author":"J Cui","year":"2019","unstructured":"Cui J, Wei X, Lv H, Li Y, Li P, Chen Z, et\u00a0al. The clinical efficacy of intravenous IgM-enriched immunoglobulin (pentaglobin) in sepsis or septic shock: a meta-analysis with trial sequential analysis. Ann Intensive Care. 2019;9:2.","journal-title":"Ann Intensive Care"},{"key":"430_CR6","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.3390\/jcm9051592","volume":"9","author":"C Giorgia","year":"2020","unstructured":"Giorgia C, Lucio T, Alessandra M, Davide Z, Egidio B, Natalia M. Pentaglobin\u00ae efficacy in reducing the incidence of sepsis and transplant-related mortality in pediatric patients undergoing hematopoietic stem cell transplantation: a retrospective study. J Clin Med. 2020;9:1592.","journal-title":"J Clin Med"},{"issue":"6","key":"430_CR7","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1097\/ACI.0000000000000696","volume":"20","author":"J Prevot","year":"2020","unstructured":"Prevot J, Jolles S. Global immunoglobulin supply: steaming towards the iceberg? Curr Opin Allergy Clin Immunol. 2020;20(6):557\u201364.","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"430_CR8","unstructured":"Organization WH. Second WHO model list of essential in vitro diagnostics. World Health Organ Tech Rep Ser. 2019."},{"key":"430_CR9","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.jaci.2010.12.475","volume":"127","author":"RU Sorensen","year":"2011","unstructured":"Sorensen RU, Hurtado R. Primary immunodeficiencies (PID)\u2014driving diagnosis for optimal care globally. J Allergy Clin Immunol. 2011;127:2.","journal-title":"J Allergy Clin Immunol"},{"key":"430_CR10","doi-asserted-by":"publisher","first-page":"25","DOI":"10.14785\/lpsn-2014-0025","volume":"2","author":"JA Hooper","year":"2015","unstructured":"Hooper JA. The history and evolution of immunoglobulin products and their clinical indications. LymphoSign J. 2015;2:25.","journal-title":"LymphoSign J"},{"key":"430_CR11","first-page":"76","volume":"63","author":"Y Guo","year":"2018","unstructured":"Guo Y, Tian X, Wang X, Xiao Z. Adverse effects of immunoglobulin therapy. Front Immunol. 2018;63:76.","journal-title":"Front Immunol"},{"key":"430_CR12","first-page":"89","volume":"56","author":"SE Svehag","year":"1991","unstructured":"Svehag SE. Adverse effects of clinical intervention on the complement system. Complement Inflamm. 1991;56:89.","journal-title":"Complement Inflamm"},{"key":"430_CR13","first-page":"80","volume":"1","author":"T Tawara","year":"2008","unstructured":"Tawara T, Hasegawa K, Sugiura Y, Harada K, Miura T, Hayashi S, et\u00a0al. Complement activation plays a key role in antibody-induced infusion toxicity in monkeys and rats. J Immunol. 2008;1:80.","journal-title":"J Immunol"},{"key":"430_CR14","first-page":"5","volume":"11","author":"LE van der Kolk","year":"2001","unstructured":"van der Kolk LE, Grillo-L\u00f3pez AJ, Baars JW, Hack CE, van Oers MHJ. Complement activation plays a key role in the side-effects of rituximab treatment. Br J Haematol. 2001;11:5.","journal-title":"Br J Haematol"},{"key":"430_CR15","first-page":"8","volume":"9","author":"A Buchacher","year":"2010","unstructured":"Buchacher A, Schluga P, M\u00fcllner J, Schreiner M, Kannicht C, Weinberger J. Anticomplementary activity of IVIG concentrates\u2014important assay parameters and impact of IgG polymers. Vox Sang. 2010;9:8.","journal-title":"Vox Sang"},{"key":"430_CR16","first-page":"6","volume":"1","author":"XX Zang","year":"1995","unstructured":"Zang XX, Sun Y, Shen F, Wang D, Zhou L, Wang J, et\u00a0al. Molecular structure alteration of IgG increased anticomplementary activity of intravenous immunoglobulin. Acta Pharmacol Sin. 1995;1:6.","journal-title":"Acta Pharmacol Sin"},{"key":"430_CR17","first-page":"5","volume":"2","author":"I Ramasamy","year":"1997","unstructured":"Ramasamy I, Tran E, Farrugia A. Measurement of anticomplementary activity in therapeutic intravenous immunoglobulin preparations. Biologicals. 1997;2:5.","journal-title":"Biologicals"},{"key":"430_CR18","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1111\/j.1537-2995.2012.03589.x","volume":"52","author":"GW Daniel","year":"2012","unstructured":"Daniel GW, Menis M, Sridhar G, Scott D, Wallace AE, Ovanesov M, et\u00a0al. Immune globulins and thrombotic adverse events as recorded in a large administrative database in 2008 through 2010. Transfusion (Paris). 2012;52:86.","journal-title":"Transfusion (Paris)"},{"key":"430_CR19","first-page":"22","volume":"25","author":"WA Germishuizen","year":"2014","unstructured":"Germishuizen WA, Gyure DC, Stubbings D, Burnouf T. Quantifying the thrombogenic potential of human plasma-derived immunoglobulin products. Biologicals. 2014;25:22.","journal-title":"Biologicals"},{"key":"430_CR20","first-page":"5","volume":"5","author":"CL Bellac","year":"2015","unstructured":"Bellac CL, Hottiger T, Jutzi MP, Bogli-Stuber K, Sanger M, Hanschmann KM, et\u00a0al. The role of isoagglutinins in intravenous immunoglobulin\u2013related hemolysis. Transfusion (Paris). 2015;5:5.","journal-title":"Transfusion (Paris)"},{"key":"430_CR21","doi-asserted-by":"crossref","unstructured":"Cuesta H, el Menyawi I, Hubsch A, Hoefferer L, Mielke O, Gabriel S, et\u00a0al. Incidence and risk factors for intravenous immunoglobulin-related hemolysis: A systematic review of clinical trial and real-world populations. Transfusion (Paris). John Wiley and Sons Inc; 2022. p. 1894\u2013907.","DOI":"10.1111\/trf.17028"},{"key":"430_CR22","first-page":"65","volume":"87","author":"G Kriv\u00e1n","year":"2022","unstructured":"Kriv\u00e1n G, Borte M, Harris JB, Lumry WR, Aigner S, Lentze S, et\u00a0al. Efficacy, safety and pharmacokinetics of a new 10% normal human immunoglobulin for intravenous infusion, BT595, in children and adults with primary immunodeficiency disease. Vox Sang. 2022;87:65.","journal-title":"Vox Sang"},{"key":"430_CR23","first-page":"25","volume":"58","author":"G Kriv\u00e1n","year":"2022","unstructured":"Kriv\u00e1n G, Borte M, Soler-Palacin P, Church JA, Csurke I, Harris JB, et\u00a0al. BT595, a 10% human normal immunoglobulin, for replacement therapy of primary immunodeficiency disease: results of a subcohort analysis in children. J Clin Immunol. 2022;58:25.","journal-title":"J Clin Immunol"},{"key":"430_CR24","first-page":"87","volume":"25","author":"J Demeter","year":"2022","unstructured":"Demeter J, Hamed A, L\u00e1szl\u00f3 S, Suvajdzic N, Aigner S, B\u00f6rner B, et\u00a0al. Efficacy and safety of BT595 (10% human intravenous immunoglobulin) in adult patients with chronic immune thrombocytopenia. Transfus Med. 2022;25:87.","journal-title":"Transfus Med"},{"key":"430_CR25","first-page":"563","volume":"3","author":"P Aucouturier","year":"1985","unstructured":"Aucouturier P, Mournir S, Preudhomme JL. Distribution of IgG subclass levels in normal adult sera as determined by a competitive enzyme immunoassay using monoclonal antibodies. Diagn Immunol. 1985;3:563.","journal-title":"Diagn Immunol"},{"key":"430_CR26","first-page":"3","volume":"1","author":"Y Tang","year":"2021","unstructured":"Tang Y, Cain P, Anguiano V, Shih JJ, Chai Q, Feng Y. Impact of IgG subclass on molecular properties of monoclonal antibodies. MAbs. 2021;1:3.","journal-title":"MAbs"},{"key":"430_CR27","doi-asserted-by":"publisher","first-page":"77","DOI":"10.15252\/embj.201591881","volume":"34","author":"G Bajic","year":"2015","unstructured":"Bajic G, Degn SE, Thiel S, Andersen GR. Complement activation, regulation, and molecular basis for complement-related diseases. EMBO J. 2015;34:77.","journal-title":"EMBO J"},{"key":"430_CR28","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1016\/j.xphs.2019.10.041","volume":"109","author":"CF Chisholm","year":"2020","unstructured":"Chisholm CF, Behnke W, Pokhilchuk Y, Frazer-Abel AA, Randolph TW. Subvisible particles in IVIg formulations activate complement in human serum. J Pharm Sci. 2020;109:996.","journal-title":"J Pharm Sci"},{"key":"430_CR29","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1111\/vox.12025","volume":"105","author":"MB Funk","year":"2013","unstructured":"Funk MB, Gross N, Gross S, Hunfeld A, Lohmann A, Guenay S, et\u00a0al. Thromboembolic events associated with immunoglobulin treatment. Vox Sang. 2013;105:88.","journal-title":"Vox Sang"},{"key":"430_CR30","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1111\/j.1423-0410.2011.01502.x","volume":"102","author":"M Etscheid","year":"2012","unstructured":"Etscheid M, Breitner-Ruddock S, Gross S, Hunfeld A, Seitz R, Dodt J. Identification of Kallikrein and FXIa as impurities in therapeutic immunoglobulins: Implications for the safety and control of intravenous blood products. Vox Sang. 2012;102:55.","journal-title":"Vox Sang"},{"key":"430_CR31","unstructured":"Roemisch J, Kaar W, Zoechling A, Kannicht C, Putz M, Kohla G, et\u00a0al. Identification of activated FXI as the major biochemical root cause in IVIG Batches associated with thromboembolic events. Analytical and experimental approaches resulting in corrective and preventive measures implemented into the octagam manufacturing process. WebmedCentral Immunotherapy. 2011;2."},{"key":"430_CR32","first-page":"66","volume":"75","author":"SK Frazier","year":"2017","unstructured":"Frazier SK, Higgins J, Bugajski A, Jones AR, Brown MR. Adverse reactions to transfusion of blood products and best practices for prevention. Crit Care Nurs Clin North Am. 2017;75:66.","journal-title":"Crit Care Nurs Clin North Am"},{"key":"430_CR33","first-page":"83","volume":"25","author":"S Basu","year":"2011","unstructured":"Basu S, Kaur R, Kaur G. Hemolytic disease of the fetus and newborn: current trends and perspectives. Asian J Transfus Sci. 2011;25:83.","journal-title":"Asian J Transfus Sci"},{"key":"430_CR34","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1371\/journal.pone.0195729","volume":"13","author":"I Kustiawan","year":"2018","unstructured":"Kustiawan I, Derksen NIL, Guhr T, Kruithof S, Jiskoot W, Vidarsson G, et\u00a0al. Dimeric IgG complexes from IVIg are incapable of inducing in vitro neutrophil degranulation or complement activation. PLoS ONE. 2018;13:25.","journal-title":"PLoS ONE"},{"key":"430_CR35","first-page":"2","volume":"2","author":"KD Ratanji","year":"2014","unstructured":"Ratanji KD, Derrick JP, Dearman RJ, Kimber I. Immunogenicity of therapeutic proteins: influence of aggregation. J Immunotoxicol. 2014;2:2.","journal-title":"J Immunotoxicol"},{"key":"430_CR36","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.cherd.2018.08.003","volume":"137","author":"PM Orlewski","year":"2018","unstructured":"Orlewski PM, Wang Y, Hosseinalipour MS, Kryscio D, Iggland M, Mazzotti M. Characterization of a vibromixer: experimental and modelling study of mixing in a batch reactor. Chem Eng Res Des. 2018;137:253.","journal-title":"Chem Eng Res Des"},{"key":"430_CR37","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.ces.2017.07.010","volume":"172","author":"R W\u00f3jtowicz","year":"2017","unstructured":"W\u00f3jtowicz R. Flow pattern and power consumption in a vibromixer. Chem Eng Sci. 2017;172:364.","journal-title":"Chem Eng Sci"},{"key":"430_CR38","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.jbiotec.2018.05.001","volume":"279","author":"A Trapp","year":"2018","unstructured":"Trapp A, Faude A, H\u00f6rold N, Schubert S, Faust S, Grob T, et\u00a0al. Multiple functions of caprylic acid-induced impurity precipitation for process intensification in monoclonal antibody purification. J Biotechnol. 2018;279:85.","journal-title":"J Biotechnol"},{"key":"430_CR39","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/0161-5890(88)90088-0","volume":"25","author":"DL Tankersley","year":"1988","unstructured":"Tankersley DL, Preston MS, Finlayson JS. Immunoglobulin G dimer: an idiotype-anti-idiotype complex. Mol Immunol. 1988;25:489.","journal-title":"Mol Immunol"},{"key":"430_CR40","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.biologicals.2009.09.002","volume":"38","author":"R Bolli","year":"2010","unstructured":"Bolli R, Woodtli K, B\u00e4rtschi M, H\u00f6fferer L, Lerch P. l-Proline reduces IgG dimer content and enhances the stability of intravenous immunoglobulin (IVIG) solutions. Biologicals. 2010;38:225.","journal-title":"Biologicals"},{"key":"430_CR41","doi-asserted-by":"crossref","unstructured":"Buchacher A, Curling JM. Current manufacturing of human plasma immunoglobulin G. Biopharmaceutical processing: development, design, and implementation of manufacturing processes. 2018.","DOI":"10.1016\/B978-0-08-100623-8.00043-8"},{"key":"430_CR42","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.molimm.2018.05.018","volume":"102","author":"JY Chen","year":"2018","unstructured":"Chen JY, Cortes C, Ferreira VP. Properdin: a multifaceted molecule involved in inflammation and diseases. Mol Immunol. 2018;102:587.","journal-title":"Mol Immunol"},{"key":"430_CR43","doi-asserted-by":"crossref","unstructured":"Hein C, Marschall V, Braun V, Sch\u00fcttrumpf J, Germer M. Rising anti-SARS-CoV-2 titer in a human immunoglobulin preparation. Int J Blood Transf Immunohematol [Internet]. 2023;13:1\u20138. Available from: https:\/\/www.ijbti.com\/archive\/article-full-text\/100076Z02CH2023","DOI":"10.5348\/100076Z02CH2023RA"},{"key":"430_CR44","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.biologicals.2016.10.003","volume":"45","author":"C Mersich","year":"2017","unstructured":"Mersich C, Ahrer K, Buchacher A, Ernegger T, Kohla G, Kannicht C, et\u00a0al. Biochemical characterization and stability of immune globulin intravenous 10% liquid (Panzyga\u00ae). Biologicals. 2017;45:33\u20138.","journal-title":"Biologicals"},{"key":"430_CR45","unstructured":"Mathew SK, Anjum F. Transfusion selective IgA deficiency. StatPearls. 2021."},{"key":"430_CR46","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1111\/cei.13665","volume":"206","author":"C Martinez","year":"2021","unstructured":"Martinez C, Wallenhorst C, van Nunen S. Intravenous immunoglobulin and the current risk of moderate and severe anaphylactic events, a cohort study. Clin Exp Immunol. 2021;206:384\u201394.","journal-title":"Clin Exp Immunol"},{"key":"430_CR47","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1016\/j.jaci.2015.04.049","volume":"136","author":"FA Bonilla","year":"2014","unstructured":"Bonilla FA, Khan DA, Ballas ZK, Chinen J, Frank MM, Hsu JT, et\u00a0al. Practice parameter for the diagnosis and management of primary immunodeficiency. J Allergy Clin Immunol. 2014;136:1186\u2013205.","journal-title":"J Allergy Clin Immunol"}],"container-title":["Drugs in R&D"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-023-00430-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40268-023-00430-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-023-00430-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T06:27:08Z","timestamp":1692340028000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40268-023-00430-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,19]]},"references-count":47,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["430"],"URL":"https:\/\/doi.org\/10.1007\/s40268-023-00430-w","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"value":"1174-5886","type":"print"},{"value":"1179-6901","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,19]]},"assertion":[{"value":"20 June 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}